Southern Sky Indica Pastilles (10:10:10) deliver 10 mg each of THC, CBD and CBN per pastille, supported by a 2.0% total terpene concentration. The blend is characterised by notable levels of Linalool (0.80% w/w), beta-Caryophyllene (0.60% w/w) and Myrcene (0.60% w/w), producing a chemotype typically associated with calming and evening-oriented use.

Southern Sky Indica Pastilles are produced in Australia using a gelatin base with MCT oil as the carrier and CO₂-extracted cannabinoids. The manufacturing process prioritises consistency across texture, cannabinoid dispersion and terpene retention, with controlled small-batch production ensuring uniformity.

Anecdotally, patients describe a gradual, settling onset with increasing calmness, physical relaxation and a sense of mental quietening. Prescribers often select this profile for patients presenting with insomnia, persistent pain syndromes and mood disturbances, with reports of a more restful and decompressing experience compared to daytime formulations.

When initiating therapy, consideration of the slower onset typical of oral cannabinoids may be beneficial. Starting with conservative titration and allowing adequate time for effects to develop is generally advised, particularly for night-time dosing.